3Ibanez B,Heusch G,Ovize M,et al.Evolving therapies for myocardial ischemia/reperfusion injury.J Am Coll Cardiol,2015,65:1454-1471.
4Communal C,Singh K,Sawyer DB,et al.Opposing effects of beta(1)-and beta(2)-adrenergic receptors on cardiac myocyte apoptosis:role of a pertussis toxin-sensitive G protein.Circulation,1999,100:2210-2212.
5Iliodromitis E K,Cohen M V,Dagres N,et al.What is wrong with cardiac conditioning?We may be shooting at moving targets.J Cardiovasc Pharmacol Ther,2015,20:357-369.
6Inafuku H,Kuniyoshi Y,Yamashiro S,et al.Determination of oxidative stress and cardiac dysfunction after ischemia/reperfusion injury in isolated rat hearts.Ann Thorac Cardiovasc Surg,2013,19:186-194.
7Hausenloy D J,Yellon D M.Survival kinases in ischemic preconditioning and postconditioning.Cardiovasc Res,2006,70:240-253.
8Sun B,Xiao J,Sun X-B,et al.Notoginsenoside R1 attenuates cardiac dysfunction in endotoxemic mice:an insight into oestrogen receptor activation and PI3K/Akt signalling.British J Pharmacol,2013,168:1758-1770.
9Ishii H,Kamikawa S,Hirohata S,et al.Eosinophil Cationic Protein Shows Survival Effect on H9c2 Cardiac Myoblast Cells with Enhanced Phosphorylation of ERK and Akt/GSK-3beta under Oxidative Stress.Acta Med Okayama,2015,69:145-153.
10Yang B,Ye D,Wang Y.Caspase-3 as a therapeutic target for heart failure.Expert Opin Ther Targets,2013,17:255-263.
